Exicure is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Co. is focus on realignment of its research and development resources to support the development of its preclinical program targeting SCN9A for neuropathic pain; the development of its partnered programs to develop Spherical Nucleic Acid, or SNA-based treatments in neuroscience targeting Huntington's disease and Angelman syndrome; the development of its partnered program to develop SNA-based treatments for hair loss disorders; and the research and development of other undisclosed therapeutic product candidates. The XCUR average annual return since 2018 is shown above.
The Average Annual Return on the XCUR average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether XCUR average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the XCUR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|